An interventional study of seropositive for Toxoplasma gondii in Toxoplasmosis Infection, Genotype II and Ocular Toxoplasmosis With Recurrences, sponsored by University Hospital, Strasbourg, France. Terminated at 1 site in France. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-09-08.
Sponsored by University Hospital, Strasbourg, France · Not applicable, Interventional, and Basic science
Ocular toxoplasmosis (OT) is a major cause of visual impairment worldwide. OT is responsible for 30 to 50% of posterior uveitis. It is characterized by dormant infections that may reactivate without known reasons, causing severe irreversible visual loss. The overall recurrence rate of OT in Europe is greater than 80% for patients and may range from one episode to 11 episodes (1% of OT) in the most extreme cases. Current treatments do not reduce the risk of recurrences and the risk of toxoplasmosis recurrence cannot be predicted in these immunocompetent patients. These clinical and biological expression changes might be related to an individual genetic susceptibility of each patient. The advanced analysis of the entire genome now possible to consider the project.
36 studies on the registry are indexed under Toxoplasmosis; 9 are open to participants now.
This study's enrollment of 16 is below the median of 105 across 20 interventional studies indexed under Toxoplasmosis.
Browse Toxoplasmosis studies →University Hospital, Strasbourg, France is the lead sponsor of 968 studies on the registry; 344 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Biological: seropositive for Toxoplasma gondii
blood sample
Highlighting of genetic mutations associated with the susceptibility to Toxoplasma gondii.severe eye recurrences. Mutation analysis will be done by exome sequencing of the subjects included in this study
Time frame: This analysis will be performed on a blood sample taken in patients included in the inclusion visit
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France